Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антагонисты рецептора ангиотензина II в нефропротекции при сахарном диабете типа 2: фокус на лозартан - Журнал Системные Гипертензии №3 (2009)
Антагонисты рецептора ангиотензина II в нефропротекции при сахарном диабете типа 2: фокус на лозартан
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Целый ряд крупных исследований убедительно доказали связь между повышенным АД и риском возникновения сердечно-сосудистых осложнений (ССО), таких как мозговой инсульт, инфаркт миокарда, сердечная недостаточность. Но ни одно исследование в сравнении с активным препаратом не доказало превосходства одного лекарственного средства над другим в отношении снижения риска ССО и смертности. В обзоре представлены данные об эффективности терапии рамиприлом в свете доказательной медицины, которые наглядно демонстрируют, наряду с хорошими антигипертензивными свойствами, эффективность в отношении возникновения новых случаев сахарного диабета и его осложнений. Высокая эффективность лозартана сочетается с низкой частотой развития побочных эффектов.
Ключевые слова: нефропротекция, сахарный диабет, лозартан
Key words: nephroprotection, diabetes mellitus, losartan
Ключевые слова: нефропротекция, сахарный диабет, лозартан
________________________________________________
Key words: nephroprotection, diabetes mellitus, losartan
Полный текст
Список литературы
1. Дедов И.И., Викулова О.К., Сухарева О.Ю., Сунцов Ю.И. Скрининг диабетической нефропатии в Российской Федерации. Сахарный диабет и хроническая болезнь почек. М., 2009; гл. 4.2: 39–59.
2. Retnakaran R, Cull CA, Thorne KI et al. Holman for the UKPDS Study Group. Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55 (6): 1832–9.
3. Renal Data System: USRDS 2003 Аnnual data report. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
4. European Dialysis and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant 1996; 11 (Suppl. 7): 1–32.
5. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2005 гг. Нефрология и диализ. 2007; 9 (1): 6–85.
6. Soler MJ, Lloveras J, Batlle D. Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system. Med Clin (Barc) 2008; 131 (6): 230–6.
7. Billet S, Aguilar F, Baudry C, Clauser E. Role of angiotensin II AT(1) receptor activation in cardiovascular diseases. Kidney Int 2008; 23: 1–6.
8. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13 (5 Pt 2): 62S–7S.
9. Dina R, Jafari M. Angiotensin II-receptor antagonists: An overview. Am J Health-Syst Pharm 2000; 57: 1231–41.
10. FDA Advisory Committee recommends approval of CosaarR to delay progression of renal disease in type 2 diabetic patients with proteinuria. [Media Release]. 2002; 12.
11. Zandbergen AA, Baggen MG, Lamberts SW et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90–6.
12. Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 2002; 18 (1): 71–6.
13. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 85–9.
14. Esmatjes E, FloresL, Inigo P et al. Effect of losartan on TGF-β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 90–3.
15. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762–9.
16. Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl. 2): 19–23.
17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.
18. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
19. Lindholm LH, Ibsen H, Dahlof B et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004–10.
20. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619–20.
21. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–9.
22. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
23. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure independent effect. Circulation 2002; 106: 672–8.
24. Marino H, Hakeda M, Babazono T et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocer, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657–64.
25. Yusuf S, Teo KK, Pogue J et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
26. Guidelines Committee. 2003 European Society of hypertension – European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
2. Retnakaran R, Cull CA, Thorne KI et al. Holman for the UKPDS Study Group. Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55 (6): 1832–9.
3. Renal Data System: USRDS 2003 Аnnual data report. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
4. European Dialysis and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant 1996; 11 (Suppl. 7): 1–32.
5. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2005 гг. Нефрология и диализ. 2007; 9 (1): 6–85.
6. Soler MJ, Lloveras J, Batlle D. Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system. Med Clin (Barc) 2008; 131 (6): 230–6.
7. Billet S, Aguilar F, Baudry C, Clauser E. Role of angiotensin II AT(1) receptor activation in cardiovascular diseases. Kidney Int 2008; 23: 1–6.
8. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13 (5 Pt 2): 62S–7S.
9. Dina R, Jafari M. Angiotensin II-receptor antagonists: An overview. Am J Health-Syst Pharm 2000; 57: 1231–41.
10. FDA Advisory Committee recommends approval of CosaarR to delay progression of renal disease in type 2 diabetic patients with proteinuria. [Media Release]. 2002; 12.
11. Zandbergen AA, Baggen MG, Lamberts SW et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90–6.
12. Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 2002; 18 (1): 71–6.
13. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 85–9.
14. Esmatjes E, FloresL, Inigo P et al. Effect of losartan on TGF-β1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 90–3.
15. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762–9.
16. Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl. 2): 19–23.
17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861–9.
18. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
19. Lindholm LH, Ibsen H, Dahlof B et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004–10.
20. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619–20.
21. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–9.
22. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
23. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure independent effect. Circulation 2002; 106: 672–8.
24. Marino H, Hakeda M, Babazono T et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocer, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657–64.
25. Yusuf S, Teo KK, Pogue J et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
26. Guidelines Committee. 2003 European Society of hypertension – European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
Авторы
О.К.Викулова, М.В.Шестакова
ФГУ Эндокринологический научный центр МЗСР, Москва
FSI Russian endocrinology scientific centre, Moscow
ФГУ Эндокринологический научный центр МЗСР, Москва
________________________________________________
FSI Russian endocrinology scientific centre, Moscow
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.